Welcome to our dedicated page for Ani Pharmaceutic news (Ticker: ANIP), a resource for investors and traders seeking the latest updates and insights on Ani Pharmaceutic stock.
ANI Pharmaceuticals, Inc. reports developments as a diversified biopharmaceutical company that develops, manufactures, and commercializes therapeutics through Rare Disease, Generics, and Brands businesses. Its Rare Disease portfolio includes Purified Cortrophin® Gel and ophthalmology products such as ILUVIEN® and YUTIQ®, while its generics portfolio includes products launched through FDA-approved abbreviated new drug applications.
ANI news commonly covers quarterly and annual financial results, guidance updates, product revenue trends, FDA approvals, generic product launches, clinical data publications, investor presentations, and capital allocation actions. Company updates also describe activity in ophthalmology, rheumatology, nephrology, neurology, and pulmonology, along with manufacturing and commercialization execution in the United States.
ANI Pharmaceuticals (NASDAQ: ANIP) will announce its fourth quarter and full year 2020 financial results on March 9, 2021. Nikhil Lalwani, President and CEO, along with Stephen P. Carey, CFO, will lead a conference call at 8:30 a.m. ET to discuss the results. Interested parties can join the call via a toll-free number or listen to a live webcast on the company’s website. A replay of the call will be available shortly after its conclusion, accessible for one week.
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) has launched Prazosin HCl Capsules USP in 1mg and 2mg, following FDA approval of its prior approval supplement application. The U.S. market for these strengths is approximately $46.2 million, as per IQVIA/IMS Health. This marks ANI's fourteenth re-commercialization of a discontinued ANDA product, showcasing its commitment to maximizing product portfolio value. Prazosin is used to treat hypertension, thereby reducing cardiovascular event risks, including strokes and heart attacks.
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) has received FDA approval for Aminocaproic Acid Tablets USP, 500mg, marking its seventh generic product launch in 2020. The U.S. market for this product is valued at approximately $12.7 million, highlighting its significance in enhancing hemostasis during bleeding situations. This launch is part of ANI's strategy to accelerate its product introductions, stemming from its acquisition of a generic pipeline from Amerigen Pharmaceuticals. The company anticipates more product launches in the future, focusing on realizing its portfolio potential.
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) reported Q3 2020 net revenues of $53.0 million, a rise from $51.3 million in Q3 2019, driven largely by a 18.8% increase in generic pharmaceutical product sales. The company posted a GAAP net income of $0.4 million and diluted EPS of $0.04. However, revenues from branded products fell 25.3%. Operating expenses rose to $50.2 million, resulting in an adjusted non-GAAP diluted EPS of $0.97, down from $1.23 year-over-year. ANI remains focused on the upcoming launch of Cortrophin Gel and CEO Nikhil Lalwani's strategy for growth.
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced it will release its third quarter 2020 financial results on November 5, 2020, before U.S. market opening. The conference call, hosted by CEO Nikhil Lalwani and CFO Stephen P. Carey, will be held at 10:30 a.m. ET. Investors can join by dialing (866) 776-8875 or via webcast at the company's website. A replay will be available for one week after the call.
ANI focuses on developing high-quality branded and generic pharmaceuticals in areas including controlled substances and oncolytics.
ANI Pharmaceuticals announced the acquisition of Fluconazole Tablets USP from a private company for $3.0 million. The product's current annual U.S. market is valued at approximately $40 million, indicating significant market opportunity. Interim President and CEO Patrick Walsh expressed enthusiasm for integrating this product into ANI's portfolio, which is expected to enhance margins and competitive positioning. Fluconazole Tablets are used primarily for treating vaginal and esophageal candidiasis, among other conditions.
ANI Pharmaceuticals announced the launch of Mexiletine Hydrochloride Capsules USP, available in 150mg, 200mg, and 250mg dosages, targeting a $16 million U.S. market. This marks ANI's sixth generic product launch in 2020 and the first from its Oakville, Canada site, which was acquired in August 2018. Mexiletine is indicated for treating life-threatening ventricular arrhythmias. The company's Interim President and CEO, Patrick Walsh, emphasized the milestone's importance for future product development.